Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ABBOTT INDIA Mar-19 |
ACTAVIS Dec-18 |
ABBOTT INDIA/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 8,834 | 14,011 | - | |
Low | Rs | 5,458 | 9,399 | - | |
Sales per share (Unadj.) | Rs | 1,731.1 | 3,437.0 | - | |
Earnings per share (Unadj.) | Rs | 211.9 | -1,107.1 | - | |
Cash flow per share (Unadj.) | Rs | 219.9 | 362.2 | - | |
Dividends per share (Unadj.) | Rs | 65.00 | 0 | - | |
Dividend yield (eoy) | % | 0.9 | 0 | - | |
Book value per share (Unadj.) | Rs | 945.2 | 14,175.9 | - | |
Shares outstanding (eoy) | m | 21.25 | 332.60 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.1 | 3.4 | 121.2% | |
Avg P/E ratio | x | 33.7 | -10.6 | -318.9% | |
P/CF ratio (eoy) | x | 32.5 | 32.3 | 100.6% | |
Price / Book Value ratio | x | 7.6 | 0.8 | 915.6% | |
Dividend payout | % | 30.7 | 0 | - | |
Avg Mkt Cap | Rs m | 151,848 | 3,893,108 | 3.9% | |
No. of employees | `000 | 3.5 | 16.9 | 20.6% | |
Total wages/salary | Rs m | 4,356 | 0 | - | |
Avg. sales/employee | Rs Th | 10,555.5 | 67,641.2 | 15.6% | |
Avg. wages/employee | Rs Th | 1,249.9 | 0 | - | |
Avg. net profit/employee | Rs Th | 1,292.2 | -21,787.3 | -5.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 36,786 | 1,143,137 | 3.2% | |
Other income | Rs m | 1,133 | 21,861 | 5.2% | |
Total revenues | Rs m | 37,919 | 1,164,997 | 3.3% | |
Gross profit | Rs m | 6,047 | 29,956 | 20.2% | |
Depreciation | Rs m | 169 | 488,666 | 0.0% | |
Interest | Rs m | 23 | 65,966 | 0.0% | |
Profit before tax | Rs m | 6,989 | -502,815 | -1.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 128,238 | 0.0% | |
Tax | Rs m | 2,485 | -6,372 | -39.0% | |
Profit after tax | Rs m | 4,503 | -368,205 | -1.2% | |
Gross profit margin | % | 16.4 | 2.6 | 627.3% | |
Effective tax rate | % | 35.6 | 1.3 | 2,806.1% | |
Net profit margin | % | 12.2 | -32.2 | -38.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 27,610 | 468,855 | 5.9% | |
Current liabilities | Rs m | 8,569 | 414,764 | 2.1% | |
Net working cap to sales | % | 51.8 | 4.7 | 1,093.9% | |
Current ratio | x | 3.2 | 1.1 | 285.0% | |
Inventory Days | Days | 60 | 20 | 307.4% | |
Debtors Days | Days | 27 | 66 | 41.3% | |
Net fixed assets | Rs m | 1,057 | 129,397 | 0.8% | |
Share capital | Rs m | 213 | 0 | - | |
Net worth | Rs m | 20,086 | 4,714,905 | 0.4% | |
Long term debt | Rs m | 0 | 1,660,289 | 0.0% | |
Total assets | Rs m | 29,409 | 7,370,469 | 0.4% | |
Interest coverage | x | 311.6 | -6.6 | -4,705.2% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 1.3 | 0.2 | 806.5% | |
Return on assets | % | 15.4 | -4.1 | -375.3% | |
Return on equity | % | 22.4 | -7.8 | -287.1% | |
Return on capital | % | 34.9 | -4.8 | -721.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,991 | 408,400 | 1.2% | |
From Investments | Rs m | -2,570 | 224,362 | -1.1% | |
From Financial Activity | Rs m | -1,428 | -700,936 | 0.2% | |
Net Cashflow | Rs m | 993 | -67,834 | -1.5% |
Compare ABBOTT INDIA With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare ABBOTT INDIA With: NOVARTIS WYETH STERLING BIOTECH ALKEM LABORATORIES DIVIS LABORATORIES
Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.
For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsIn this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.
A look at what India's top equity mutual funds bought and sold in January 2021.
More